Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): A phase II trial

H. Sun,X. Zhu,Q. Gao,S. Qiu,Y. Shi,X. Wang,X. Huang,X. Yang,Y. Ji, Y. Pang,Y. He,Y. Xu,M. Li,J. Zhu,Y. Shen,C. Huang,J. Zhou, J. Fan

ANNALS OF ONCOLOGY（2022）

引用 2|浏览5

暂无评分

摘要

The combination treatment using sintilimab (a PD-1 antibody) and bevacizumab (bev) biosimilar improved PFS and OS in unresectable or advanced HCC as compared with sorafenib in ORIENT-32 study and was approved as first-line treatment for unresectable HCC in China. We assessed the efficacy and safety of the combination therapy as conversion therapy for potentially resectable intermediate stage HCC.

查看译文

关键词

hepatocellular carcinoma,bevacizumab biosimilar

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要